Abstract 10879: Risk of Renal Failure With Multivessel vs. Culprit-Lesion Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock: An Updated Meta-Analysis

IntroductionThere is considerable debate regarding the optimal revascularization strategy in patients with acute myocardial infarction (AMI) complicated by cardiogenic shock (CS), particularly regarding the management of non-culprit lesions. Although MV-PCI is thought to prevent recurrent ischemia i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Circulation (New York, N.Y.) N.Y.), 2018-11, Vol.138 (Suppl_1 Suppl 1), p.A10879-A10879
Hauptverfasser: Kundu, Amartya, Sardar, Partha, Kakouros, Nikolaos, Dawn Abbott, Jinnette, Fisher, Daniel Z
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page A10879
container_issue Suppl_1 Suppl 1
container_start_page A10879
container_title Circulation (New York, N.Y.)
container_volume 138
creator Kundu, Amartya
Sardar, Partha
Kakouros, Nikolaos
Dawn Abbott, Jinnette
Fisher, Daniel Z
description IntroductionThere is considerable debate regarding the optimal revascularization strategy in patients with acute myocardial infarction (AMI) complicated by cardiogenic shock (CS), particularly regarding the management of non-culprit lesions. Although MV-PCI is thought to prevent recurrent ischemia in non-infarct related lesions, one of the major safety concerns is the risk of contrast induced renal failure from use of more contrast dye with MV-PCI.MethodsWe conducted an updated meta-analysis of studies comparing multivessel (MV-PCI) versus culprit lesion-only percutaneous coronary intervention (CL-PCI), in patients with AMI and CS. We searched PubMed, MEDLINE, CINHAL, Cochrane CENTRAL, EMBASE, Web of Science and Google Scholar databases from inception through April 30, 2018. Only studies reporting data on renal failure were included in this analysis. Renal failure was generally defined as a new requirement for renal replacement therapy at short-term follow up (In-hospital/30 days). Pooled odds ratios (OR) and 95% confidence intervals (CI) were estimated using the random-effects models of DerSimonian and Laird. Statistical analysis was done in line with recommendations from the Cochrane Collaboration using Review Manager (RevMan) version 5.3ResultsA total of 8 studies (7 observational, 1 RCT) involving 6596 patients (1572 undergoing MV-PCI and 5024 undergoing CL-PCI) were included in the final analysis. Renal Failure was noted in a total of 519 (7.8 %) patients (156 in MV-PCI group and 363 in CL-PCI group). Compared to CL-PCI, there was no significant difference in the risk of renal failure with MV-PCI [9.9 % vs. 7.2 %; OR 1.19; 95% CI 0.84-1.68, p=0.3, I =52 %] (Figure).ConclusionsOur analysis suggests that MV-PCI is not associated with an increased risk of renal failure compared to CL-PCI, in patients with AMI and CS.
format Article
fullrecord <record><control><sourceid>wolterskluwer</sourceid><recordid>TN_cdi_wolterskluwer_health_00003017-201811061-00225</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>00003017-201811061-00225</sourcerecordid><originalsourceid>FETCH-wolterskluwer_health_00003017-201811061-002253</originalsourceid><addsrcrecordid>eNqdkO9KwzAUxYsoOP-8w32BSNKu67ZvpTgcOJCp-HFk6Z2Ni0nJTTv6nj7QsukT-Olw4HfuOdyLZCTydMzGeTa7TEac8xkrsjS9Tm6IvqKdZEU-Sn7KLQUvVQDBp8VsDmtNe3A7WKOVBhZSm84jfOjQwKozQfdIhAZ6eoCqM63XgT0jaWfhBb3qgrToOoLKeWelH2BpA_oebTghOlIy6Ojo92QZEwirwSnpax0Ll3YnvTrDlftujVYyYA3bAaoT4T7RagWvjVP7OZQW3tv6DKwwSFbGyQNpukuudtIQ3v_pbTJePL5VT-zgTFxDe9Md0G8alCY0m_gLnnFRsJSLqRB8IhjnaZpn_4wdAYugd2o</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Abstract 10879: Risk of Renal Failure With Multivessel vs. Culprit-Lesion Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock: An Updated Meta-Analysis</title><source>American Heart Association Journals</source><source>Journals@Ovid Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Kundu, Amartya ; Sardar, Partha ; Kakouros, Nikolaos ; Dawn Abbott, Jinnette ; Fisher, Daniel Z</creator><creatorcontrib>Kundu, Amartya ; Sardar, Partha ; Kakouros, Nikolaos ; Dawn Abbott, Jinnette ; Fisher, Daniel Z</creatorcontrib><description>IntroductionThere is considerable debate regarding the optimal revascularization strategy in patients with acute myocardial infarction (AMI) complicated by cardiogenic shock (CS), particularly regarding the management of non-culprit lesions. Although MV-PCI is thought to prevent recurrent ischemia in non-infarct related lesions, one of the major safety concerns is the risk of contrast induced renal failure from use of more contrast dye with MV-PCI.MethodsWe conducted an updated meta-analysis of studies comparing multivessel (MV-PCI) versus culprit lesion-only percutaneous coronary intervention (CL-PCI), in patients with AMI and CS. We searched PubMed, MEDLINE, CINHAL, Cochrane CENTRAL, EMBASE, Web of Science and Google Scholar databases from inception through April 30, 2018. Only studies reporting data on renal failure were included in this analysis. Renal failure was generally defined as a new requirement for renal replacement therapy at short-term follow up (In-hospital/30 days). Pooled odds ratios (OR) and 95% confidence intervals (CI) were estimated using the random-effects models of DerSimonian and Laird. Statistical analysis was done in line with recommendations from the Cochrane Collaboration using Review Manager (RevMan) version 5.3ResultsA total of 8 studies (7 observational, 1 RCT) involving 6596 patients (1572 undergoing MV-PCI and 5024 undergoing CL-PCI) were included in the final analysis. Renal Failure was noted in a total of 519 (7.8 %) patients (156 in MV-PCI group and 363 in CL-PCI group). Compared to CL-PCI, there was no significant difference in the risk of renal failure with MV-PCI [9.9 % vs. 7.2 %; OR 1.19; 95% CI 0.84-1.68, p=0.3, I =52 %] (Figure).ConclusionsOur analysis suggests that MV-PCI is not associated with an increased risk of renal failure compared to CL-PCI, in patients with AMI and CS.</description><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><language>eng</language><publisher>by the American College of Cardiology Foundation and the American Heart Association, Inc</publisher><ispartof>Circulation (New York, N.Y.), 2018-11, Vol.138 (Suppl_1 Suppl 1), p.A10879-A10879</ispartof><rights>2018 by the American College of Cardiology Foundation and the American Heart Association, Inc.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Kundu, Amartya</creatorcontrib><creatorcontrib>Sardar, Partha</creatorcontrib><creatorcontrib>Kakouros, Nikolaos</creatorcontrib><creatorcontrib>Dawn Abbott, Jinnette</creatorcontrib><creatorcontrib>Fisher, Daniel Z</creatorcontrib><title>Abstract 10879: Risk of Renal Failure With Multivessel vs. Culprit-Lesion Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock: An Updated Meta-Analysis</title><title>Circulation (New York, N.Y.)</title><description>IntroductionThere is considerable debate regarding the optimal revascularization strategy in patients with acute myocardial infarction (AMI) complicated by cardiogenic shock (CS), particularly regarding the management of non-culprit lesions. Although MV-PCI is thought to prevent recurrent ischemia in non-infarct related lesions, one of the major safety concerns is the risk of contrast induced renal failure from use of more contrast dye with MV-PCI.MethodsWe conducted an updated meta-analysis of studies comparing multivessel (MV-PCI) versus culprit lesion-only percutaneous coronary intervention (CL-PCI), in patients with AMI and CS. We searched PubMed, MEDLINE, CINHAL, Cochrane CENTRAL, EMBASE, Web of Science and Google Scholar databases from inception through April 30, 2018. Only studies reporting data on renal failure were included in this analysis. Renal failure was generally defined as a new requirement for renal replacement therapy at short-term follow up (In-hospital/30 days). Pooled odds ratios (OR) and 95% confidence intervals (CI) were estimated using the random-effects models of DerSimonian and Laird. Statistical analysis was done in line with recommendations from the Cochrane Collaboration using Review Manager (RevMan) version 5.3ResultsA total of 8 studies (7 observational, 1 RCT) involving 6596 patients (1572 undergoing MV-PCI and 5024 undergoing CL-PCI) were included in the final analysis. Renal Failure was noted in a total of 519 (7.8 %) patients (156 in MV-PCI group and 363 in CL-PCI group). Compared to CL-PCI, there was no significant difference in the risk of renal failure with MV-PCI [9.9 % vs. 7.2 %; OR 1.19; 95% CI 0.84-1.68, p=0.3, I =52 %] (Figure).ConclusionsOur analysis suggests that MV-PCI is not associated with an increased risk of renal failure compared to CL-PCI, in patients with AMI and CS.</description><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqdkO9KwzAUxYsoOP-8w32BSNKu67ZvpTgcOJCp-HFk6Z2Ni0nJTTv6nj7QsukT-Olw4HfuOdyLZCTydMzGeTa7TEac8xkrsjS9Tm6IvqKdZEU-Sn7KLQUvVQDBp8VsDmtNe3A7WKOVBhZSm84jfOjQwKozQfdIhAZ6eoCqM63XgT0jaWfhBb3qgrToOoLKeWelH2BpA_oebTghOlIy6Ojo92QZEwirwSnpax0Ll3YnvTrDlftujVYyYA3bAaoT4T7RagWvjVP7OZQW3tv6DKwwSFbGyQNpukuudtIQ3v_pbTJePL5VT-zgTFxDe9Md0G8alCY0m_gLnnFRsJSLqRB8IhjnaZpn_4wdAYugd2o</recordid><startdate>20181106</startdate><enddate>20181106</enddate><creator>Kundu, Amartya</creator><creator>Sardar, Partha</creator><creator>Kakouros, Nikolaos</creator><creator>Dawn Abbott, Jinnette</creator><creator>Fisher, Daniel Z</creator><general>by the American College of Cardiology Foundation and the American Heart Association, Inc</general><scope/></search><sort><creationdate>20181106</creationdate><title>Abstract 10879: Risk of Renal Failure With Multivessel vs. Culprit-Lesion Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock: An Updated Meta-Analysis</title><author>Kundu, Amartya ; Sardar, Partha ; Kakouros, Nikolaos ; Dawn Abbott, Jinnette ; Fisher, Daniel Z</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-wolterskluwer_health_00003017-201811061-002253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Kundu, Amartya</creatorcontrib><creatorcontrib>Sardar, Partha</creatorcontrib><creatorcontrib>Kakouros, Nikolaos</creatorcontrib><creatorcontrib>Dawn Abbott, Jinnette</creatorcontrib><creatorcontrib>Fisher, Daniel Z</creatorcontrib><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kundu, Amartya</au><au>Sardar, Partha</au><au>Kakouros, Nikolaos</au><au>Dawn Abbott, Jinnette</au><au>Fisher, Daniel Z</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Abstract 10879: Risk of Renal Failure With Multivessel vs. Culprit-Lesion Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock: An Updated Meta-Analysis</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><date>2018-11-06</date><risdate>2018</risdate><volume>138</volume><issue>Suppl_1 Suppl 1</issue><spage>A10879</spage><epage>A10879</epage><pages>A10879-A10879</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><abstract>IntroductionThere is considerable debate regarding the optimal revascularization strategy in patients with acute myocardial infarction (AMI) complicated by cardiogenic shock (CS), particularly regarding the management of non-culprit lesions. Although MV-PCI is thought to prevent recurrent ischemia in non-infarct related lesions, one of the major safety concerns is the risk of contrast induced renal failure from use of more contrast dye with MV-PCI.MethodsWe conducted an updated meta-analysis of studies comparing multivessel (MV-PCI) versus culprit lesion-only percutaneous coronary intervention (CL-PCI), in patients with AMI and CS. We searched PubMed, MEDLINE, CINHAL, Cochrane CENTRAL, EMBASE, Web of Science and Google Scholar databases from inception through April 30, 2018. Only studies reporting data on renal failure were included in this analysis. Renal failure was generally defined as a new requirement for renal replacement therapy at short-term follow up (In-hospital/30 days). Pooled odds ratios (OR) and 95% confidence intervals (CI) were estimated using the random-effects models of DerSimonian and Laird. Statistical analysis was done in line with recommendations from the Cochrane Collaboration using Review Manager (RevMan) version 5.3ResultsA total of 8 studies (7 observational, 1 RCT) involving 6596 patients (1572 undergoing MV-PCI and 5024 undergoing CL-PCI) were included in the final analysis. Renal Failure was noted in a total of 519 (7.8 %) patients (156 in MV-PCI group and 363 in CL-PCI group). Compared to CL-PCI, there was no significant difference in the risk of renal failure with MV-PCI [9.9 % vs. 7.2 %; OR 1.19; 95% CI 0.84-1.68, p=0.3, I =52 %] (Figure).ConclusionsOur analysis suggests that MV-PCI is not associated with an increased risk of renal failure compared to CL-PCI, in patients with AMI and CS.</abstract><pub>by the American College of Cardiology Foundation and the American Heart Association, Inc</pub></addata></record>
fulltext fulltext
identifier ISSN: 0009-7322
ispartof Circulation (New York, N.Y.), 2018-11, Vol.138 (Suppl_1 Suppl 1), p.A10879-A10879
issn 0009-7322
1524-4539
language eng
recordid cdi_wolterskluwer_health_00003017-201811061-00225
source American Heart Association Journals; Journals@Ovid Complete; EZB-FREE-00999 freely available EZB journals
title Abstract 10879: Risk of Renal Failure With Multivessel vs. Culprit-Lesion Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock: An Updated Meta-Analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T08%3A23%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wolterskluwer&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Abstract%2010879:%20Risk%20of%20Renal%20Failure%20With%20Multivessel%20vs.%20Culprit-Lesion%20Percutaneous%20Coronary%20Intervention%20in%20Patients%20With%20Acute%20Myocardial%20Infarction%20Complicated%20by%20Cardiogenic%20Shock:%20An%20Updated%20Meta-Analysis&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=Kundu,%20Amartya&rft.date=2018-11-06&rft.volume=138&rft.issue=Suppl_1%20Suppl%201&rft.spage=A10879&rft.epage=A10879&rft.pages=A10879-A10879&rft.issn=0009-7322&rft.eissn=1524-4539&rft_id=info:doi/&rft_dat=%3Cwolterskluwer%3E00003017-201811061-00225%3C/wolterskluwer%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true